Ipamorelin is a selective synthetic peptide that triggers growth hormone release from the pituitary, used to raise GH and IGF-1 levels for recovery, body composition, and anti-aging purposes.
What it does
Ipamorelin is a pentapeptide (a chain of five amino acids) that mimics ghrelin, the stomach-derived hormone that signals hunger and stimulates growth hormone release. It binds a receptor on the pituitary gland called GHS-R1a, which sets off an intracellular signaling cascade — phospholipase C activates, calcium floods into the cell, and stored GH granules are released into the bloodstream. This is a fundamentally different signaling route than GHRH-based peptides like CJC-1295, which work through a cAMP pathway. Because the two mechanisms act on separate pathways that both converge on GH release, combining them produces a synergistic spike — roughly 2–4 times greater than either alone.
What makes ipamorelin stand out among GH secretagogues (compounds that stimulate GH secretion) is its selectivity. Raun et al. demonstrated that ipamorelin produces robust GH release without meaningfully raising cortisol, prolactin, or ACTH — stress and adrenal hormones that other GHRPs like GHRP-2 and GHRP-6 tend to elevate Raun 1998. It also suppresses somatostatin, the hypothalamic hormone that normally dampens GH release — effectively pressing the accelerator and releasing the brake at the same time. Unlike GHRP-6, ipamorelin causes only mild, short-lived hunger that typically resolves within 30 minutes.
Downstream, the GH pulse drives the liver to produce IGF-1 (insulin-like growth factor 1), which rises roughly 1.5–3x above baseline. IGF-1 is the primary mediator of GH's anabolic effects: it activates satellite cells (muscle stem cells involved in repair), promotes lipolysis (fat breakdown), supports collagen synthesis, and enhances slow-wave sleep depth.
What the evidence shows
GH and IGF-1 elevation / body composition Strong preclinical evidence; selectivity data from one key animal study; limited controlled human trials
The foundational selectivity data comes from Raun et al. 1998, which showed ipamorelin dose-dependently increased GH in rats without the cortisol or ACTH spikes seen with GHRP-2 and GHRP-6 Raun 1998. GHS-R1a imaging work has further characterized the receptor binding profile that underlies this selectivity M 2018. Human trials directly measuring body composition outcomes with ipamorelin alone are sparse in the published literature; most available evidence is extrapolated from animal models or from self-reported protocols combining ipamorelin with CJC-1295.
Post-operative gastrointestinal recovery (ileus) Two registered human trials; results not fully published in peer-reviewed literature
Two clinical trials registered with ClinicalTrials.gov investigated ipamorelin specifically for post-operative ileus — the temporary shutdown of bowel motility that commonly follows abdominal surgery NCT00672074, NCT01280344. GHS-R1a receptors are expressed throughout the gut, and ghrelin mimetics are known to accelerate GI motility. These trials focused on safety and efficacy in a surgical recovery context, but full peer-reviewed results have not been widely published, limiting conclusions. The gastrointestinal angle is pharmacologically coherent given the receptor distribution.
Chemotherapy-related weight loss and nausea Animal model only (ferret); no human data
A 2024 study in ferrets compared ipamorelin to anamorelin (a related GHS-R1a agonist) in cisplatin-treated animals. Ipamorelin attenuated cisplatin-induced weight loss, though anamorelin showed the additional benefit of central anti-emetic (anti-nausea) effects Zengbing 2024. This is preclinical only — ferrets are a standard model for chemotherapy-induced nausea — and no human trials on ipamorelin for cachexia or chemotherapy support have been published.
How it's used
In studies and self-reported protocols, doses range from 100 mcg once daily (typically pre-bedtime) to 300 mcg administered two to three times daily. The subcutaneous (under the skin, usually abdomen) route is standard given the peptide's short half-life of approximately two hours. Timing is considered important: doses are generally taken 30 or more minutes away from meals, since elevated insulin from food can blunt the GH pulse. A bedtime dose is commonly used to align with the body's natural nocturnal GH secretion. When combined with a GHRH analog like CJC-1295, the two are typically injected simultaneously to exploit the complementary signaling pathways.
Side effects and safety
Ipamorelin's selectivity profile means it avoids the cortisol and prolactin elevations associated with less selective GHRPs Raun 1998. Commonly reported mild effects include transient water retention, mild hunger (shorter-lived than with GHRP-6), and injection site reactions. Some users report headache, lightheadedness, or tingling in the extremities, particularly at higher doses — likely related to the GH spike itself rather than off-target receptor activity. These effects typically resolve as the body adjusts.
The more serious concern applies to anyone with active or history of GH-responsive tumors: GH and IGF-1 elevation can theoretically accelerate tumor growth, which is why active malignancy is an absolute contraindication. Ipamorelin also elevates blood glucose transiently via GH's insulin-antagonizing effects, making monitoring important in people with diabetes. Long-term effects on pituitary function, IGF-1 trajectories, and cancer risk from sustained use have not been studied in humans — this is a genuine unknown, not a theoretical one.
Bottom line
Ipamorelin has the cleanest selectivity profile among GH secretagogues studied to date, with solid animal evidence and a plausible mechanism, but human efficacy data outside of GI motility trials remains thin. It's a reasonable research candidate for those interested in GH augmentation who want to minimize cortisol and prolactin side effects compared to older GHRPs. Anyone with a history of cancer, active diabetes, or other GH-sensitive conditions should treat the contraindications seriously.